Device Trial Radar · NCT04543240
Bacterial Load for Integra™ in Operative Wounds
Last checked: Nov 19, 2026Latest source record: Sep 11, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
54
Planned (sponsor's estimate)
Start
Dec 14, 2017
Primary completion
Jan 1, 2021
Study completion Jan 1, 2021
Sponsor
- Lead sponsor
- Georgetown UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Integra LifeSciences Corporation
- First posted
- Sep 10, 2020
Design
- Study type
- Observational
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years, up to 90 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Proportion of postoperative complications (infections, dehiscence, graft slough) after initial application of Integra™
Conditions
- Wounds and Injuries
Interventions
Integra™ dermal regeneration templateDevice
Integra a biologic dressing for deep wounds or large soft tissue defects that penetrate to the level of bone
Primary outcomes
What the sponsor says the trial is designed to measure.
- Determine a threshold in which Integra is tolerant to bacteria that yields positive results (healing). The investigators believe that this device is more tolerant to bacterial load then current perception.Time frame: 1 year
Locations
1 site in 1 country. Site status is shown where the registry gives one.
MedStar Georgetown University Hospital
Washington D.C., District of Columbia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.